Regeneron Pharmaceuticals Aktie News

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

November's Wall Street obsession hasn't been AI. It's been healthcare.

First and only FDA-approved treatment  for RVO indicated for up to every 8-week dosing after an initial monthly dosing period

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival in CSCC in the adjuvant setting, reducing the risk of recurrence or death by 68% (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p

Regeneron Pharmaceuticals, Inc. ( REGN ) Jefferies London Healthcare Conference 2025 November 17, 2025 10:30 AM EST Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Christopher Fenimore - Executive VP of Finance & CFO Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Di...

Regeneron Pharmaceuticals, Inc. ( REGN ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 9:20 AM EST Company Participants Mark Hudson - Investor Relations Executive Isreal Lowy - Senior Vice President of Clinical Development Unit Head & Oncology Justin Holko Conference Call Participants Alexandria Hammond - Wolfe Research, LLC Presentation Alexandria Hammond Wolfe Research, LL...

Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this setting

These two healthcare giants have impressive growth potential for different reasons. Eli Lilly is getting a lot of attention for its GLP-1 successes, and another blockbuster could be just around the corner.